Maryann Conover, RN | |
21 Colonial Ave, Pitman, NJ 08071-1101 | |
(856) 589-2479 | |
Not Available |
Full Name | Maryann Conover |
---|---|
Gender | Female |
Speciality | Registered Nurse - Neonatal Intensive Care |
Location | 21 Colonial Ave, Pitman, New Jersey |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1447709977 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
163WN0002X | Registered Nurse - Neonatal Intensive Care | 26NO11671600 (New Jersey) | Primary |
Mailing Address | Practice Location Address |
---|---|
Maryann Conover, RN 21 Colonial Ave, Pitman, NJ 08071-1101 Ph: (856) 589-2479 | Maryann Conover, RN 21 Colonial Ave, Pitman, NJ 08071-1101 Ph: (856) 589-2479 |
News Archive
An important focus of medical research today is on translating new scientific discoveries into advances in clinical care that will lead to meaningful improvements in health outcomes. Ongoing ethical, legal, and social issues in this era of "translational" research are the subject of a special symposium in the October issue of The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation.
The University of South Florida (USF) has received a $1.57 million U.S. Department of Defense grant to conduct translational research on traumatic brain injury and other battlefield related injuries and diseases.
Mechanical bowel preparations are commonly administered preoperatively to patients who undergo a pancreaticoduodenectomy (Whipple procedure) to treat benign and malignant tumors of the pancreas, common bile duct or duodenum. MBPs are employed as a preventative measure in gastrointestinal surgery but their effectiveness in reducing perioperative infectious complications remains unclear.
Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.
› Verified 3 days ago